Shire On Course For 2017 Launch Of 'Adderall Beads' For Adult ADHD

Shire's positive topline data from a pediatric Phase III trial of SHP465 (triple-bead mixed amphetamine salts) addresses the US FDA requirements for a class 2 resubmission for the product's NDA, said the company. The product is slated for US launch in 2017.